Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28632273 | 1.00 | STING1 (0.72) | STING1CYP3A4 | |
| SCHEMBL28632668 | 0.96 | STING1 (0.70) | STING1CYP3A4 | |
| SCHEMBL28645980 | 0.96 | STING1 (0.70) | STING1CYP3A4 | |
| SCHEMBL28645982 | 0.96 | STING1 (0.70) | STING1CYP3A4 | |
| SCHEMBL28632667 | 0.96 | STING1 (0.70) | STING1CYP3A4 | |
| SCHEMBL21157502 | 0.91 | STING1 (0.60) | STING1CYP3A4 | |
| SCHEMBL21156986 | 0.91 | STING1 (0.81) | STING1CYP3A4 | |
| SCHEMBL21156966 | 0.89 | STING1 (0.80) | STING1CYP3A4 | |
| SCHEMBL21156968 | 0.88 | STING1 (0.74) | STING1CYP3A4 | |
| SCHEMBL21157499 | 0.88 | STING1 (0.81) | STING1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11155567-B2 | Sting agonist compounds and methods of use | MERSANA THERAPEUTICS, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| CN-110016025-B | Immunomodulator | 成都先导药物开发股份有限公司 | 2021-08-06 | — | — | CN | disclosed |
| US-20210032269-A1 | STING AGONIST COMPOUNDS AND METHODS OF USE | MERSANA THERAPEUTICS, INC. | 2021-02-04 | — | — | US | disclosed |
| WO-2019134705-A1 | IMMUNOMODULATOR | 成都先导药物开发股份有限公司 | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11155567-B2 | Sting agonist compounds and methods of use | STING1, IRF3, MAVS | STING1 1/4885CYP3A4 4415/4885 |
| US-20210032269-A1 | STING AGONIST COMPOUNDS AND METHODS OF USE | STING1, IRF3, MAVS | STING1 1/4885CYP3A4 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.